Intranasal Corticosteroid Spray Examples
Multiple intranasal corticosteroid formulations are FDA-approved and available for treating allergic rhinitis, including both first-generation agents (beclomethasone dipropionate, triamcinolone acetonide, flunisolide, budesonide) and second-generation agents (fluticasone propionate, fluticasone furoate, mometasone furoate, ciclesonide). 1, 2
Available Intranasal Corticosteroid Agents
First-Generation Intranasal Corticosteroids
- Beclomethasone dipropionate - Available in aqueous formulation 2, 3
- Budesonide (Rhinocort) - Aqueous nasal spray, 32 µg per spray, approved for ages ≥6 years, available over-the-counter 1, 2
- Triamcinolone acetonide (Nasacort) - Aqueous spray, 55 µg per spray, approved for ages ≥2 years, available over-the-counter 1, 2
- Flunisolide - Available formulation 2, 3
Second-Generation Intranasal Corticosteroids
- Fluticasone propionate (Flonase) - Aqueous suspension, 50 µg per spray, approved for ages ≥4 years, available over-the-counter 1, 2
- Fluticasone furoate (Veramyst) - Suspension, 27.5 µg per spray, approved for ages ≥2 years, prescription only 1, 4
- Mometasone furoate (Nasonex) - Aqueous formulation, 50 µg per spray, approved for ages ≥2 years, prescription only 1, 2
- Ciclesonide (Omnaris) - Aqueous suspension, 50 µg per spray, approved for ages ≥6 years, prescription only 1
- Ciclesonide (Zetonna) - HFA-propelled aerosol, 37 µg per spray, approved for ages ≥12 years, prescription only 1
Clinical Considerations
Efficacy Profile
All intranasal corticosteroids demonstrate similar efficacy when used at recommended doses, representing the most effective monotherapy class for controlling all four major symptoms of allergic rhinitis: sneezing, itching, rhinorrhea, and nasal congestion 1. The clinical response does not vary significantly between currently available intranasal corticosteroid formulations 1.
Onset of Action
Therapeutic effect typically occurs within 12 hours, with some patients experiencing benefit as early as 3-4 hours after administration 1. Full therapeutic benefit may require several days to weeks of continuous use 1.
Safety Considerations
When administered at recommended doses, intranasal corticosteroids are not generally associated with clinically significant systemic side effects in adults 1. In children, growth effects may occur with certain agents (particularly beclomethasone dipropionate at higher doses), but fluticasone propionate, mometasone furoate, and budesonide show no effect on growth at recommended doses 1.
Pregnancy Safety
Budesonide carries a pregnancy category B rating, making it the preferred intranasal corticosteroid during pregnancy 5. Fluticasone furoate, mometasone, and budesonide are considered safe at recommended therapeutic doses after proper medical evaluation 6. Intranasal triamcinolone has been associated with respiratory tract defects and should be avoided 6.
Common Adverse Effects
Local side effects include nasal irritation, epistaxis (5-10% of patients), burning, stinging, and headache 1, 2. Patients should direct sprays away from the nasal septum to minimize risk of mucosal erosions and rare septal perforation 1.